CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board
01 February 2022 - 9:30PM
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand, and
treat rare diseases, today announced the nomination of Prof.
Andreas Busch as a member of the Supervisory Board, which will be
proposed to the shareholders at the next General Meeting. Dr. Busch
will also serve with immediate effect as a member ad interim of the
Company’s Supervisory Board.
“We are very pleased to welcome Dr. Busch as a new
member of the Supervisory Board,” stated Peer Schatz, Chairman of
the Supervisory Board of CENTOGENE. “Andreas has been instrumental
in accelerating the discovery and development of novel approaches
and treatments in rare diseases and has successfully guided
innovation and value creation for patients and stakeholders in
large pharmaceutical companies. We look forward to benefiting from
his contributions as CENTOGENE accelerates value creation as the
unique and essential partner for data-driven insights to biopharma
and pharmaceutical companies for rare, metabolic, and
neurodegenerative diseases.” “I am excited by the opportunity to
join CENTOGENE,” said Dr. Busch. “This is a unique time to join
CENTOGENE, as it has built an industry-leading Bio/Databank to
accelerate and de-risk drug programs along their entire development
timeline. I believe there is tremendous opportunity to accelerate
this effort and become the partner of choice for biopharma in the
company’s key disease areas.”
Dr. Busch brings over 20 years of experience and
leadership in the pharmaceutical industry. Since 2019, he has
served as Chief Innovation Officer and Chief Scientific Officer at
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage
biopharmaceutical company on a mission to develop treatments that
restore cognitive function. Prior to this, Dr. Busch served as Head
of R&D and CSO at Shire plc., a global biotechnology leader
serving patients with rare diseases. Previously, he held a variety
of senior leadership positions in his 13-year tenure at Bayer
group, most recently as Head of Drug Discovery and a member of the
Executive Committee for the Pharmaceuticals division of Bayer.
Prior to joining Bayer, Dr. Busch was Global Head of Cardiovascular
Research at Hoechst and Sanofi-Aventis.
Dr. Busch has served as a member of numerous
Supervisory and Scientific Boards of research institutions and
companies, including the German Cancer Research Center, the
University of Tübingen, the Max Delbrück Center, and the Max Planck
Institute of Molecular Genetics, as well as Takeda and start-up
companies, such as Omeicos and BerlinCures. He also holds the title
of Extraordinary Professor of Pharmacology at the Johann Wolfgang
Goethe-University in Frankfurt, Germany. Dr. Busch received his
license to practice Pharmacy and Ph.D. in Pharmacology from the
Johann-Wolfgang-Goethe-University, Frankfurt. He is the author of
over 400 publications and abstracts, and received the prestigious
Sir Bernard Katz and Franz Volhard Awards for his work on renal and
cardiac ion channels and transporters.
About CENTOGENE
CENTOGENE engages in diagnosis and research around
rare diseases transforming real-world clinical, genetic, and
multiomic data to diagnose, understand, and treat rare diseases.
Our goal is to bring rationality to treatment decisions and to
accelerate the development of new orphan drugs by using our
extensive rare disease knowledge and data. CENTOGENE has developed
a global proprietary rare disease platform based on our real-world
data repository of over 600,000 patients representing over 120
different countries.
CENTOGENE’s platform includes epidemiologic,
phenotypic, and genetic data that reflects a global population, as
well as a biobank of patients’ blood samples and cell cultures.
CENTOGENE believes this represents the only platform focused on
comprehensive analysis of multi-level data to improve the
understanding of rare hereditary diseases. It allows for better
identification and stratification of patients and their underlying
diseases to enable and accelerate discovery, development, and
access to orphan drugs. As of December 31, 2020, CENTOGENE
collaborated with over 30 pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Statements contained herein that are not clearly historical in
nature are forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Ben Legg Corporate
Communications Press@centogene.com
Lennart Streibel Investor Relations
Investor.Relations@centogene.com Stern
IR Brendan Payne +1 (212) 698 8695
brendan.payne@sternir.com
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Jul 2023 to Jul 2024